Streetbeat News

Regulatory

BA

FAA Chief Whitaker visited Seattle to receive feedback from employees on Boeing oversight. The FAA is expanding oversight of new aircraft, including increased presence at Boeing facilities.

Portfolio Pulse from Benzinga Newsdesk

February 15, 2024 | 2:46 pm

MMSI

Merit Medical has received FDA 510(k) clearance for its SCOUT MD Surgical Guidance System, marking a significant regulatory milestone for the company.

Portfolio Pulse from Benzinga Newsdesk

February 15, 2024 | 2:27 pm

SATS

The Buxton Helmsley Group, Inc. (BHG), an investment fund manager, has issued multiple open letters to EchoStar Corporation's (NASDAQ:SATS) Board of Directors, alleging serious financial mismanagement, including undisclosed asset value depreciation and potential multibillion-dollar accounting and securities fraud. Despite these allegations and the material decline in EchoStar's trading values, the company has not publicly responded or indicated any internal investigation.

Portfolio Pulse from Benzinga Newsdesk

February 15, 2024 | 2:08 pm

BTCUSD

CSCO

ETHUSD

LMT

PFE

Cryptocurrencies surge with Bitcoin's market cap surpassing $1 trillion, potentially hitting $60K. US markets see mixed movements, with Cisco issuing a weak outlook. Global politics and economy updates include sanctions on Russia and BRICS nations challenging G7 dominance. Tech highlights include Uber's price target boost and Apple's AI chip advancements. Electric Vehicle sector notes Tesla's market strategies and challenges. New York City sues major social platforms over mental health concerns. Pfizer settles a lawsuit, and Lockheed Martin faces budget cuts on F-35 orders.

Portfolio Pulse from Akanksha Bakshi

February 15, 2024 | 2:02 pm

SPY

VGK

Brainard emphasized the importance of Russia compensating for the war in Ukraine, highlighting potential geopolitical and economic implications.

Portfolio Pulse from Benzinga Newsdesk

February 15, 2024 | 2:01 pm

SPY

Brainard has called for grocery stores and retail chains that increased prices during the pandemic to reduce them now. This statement could influence consumer expectations and market sentiment, potentially impacting sectors related to consumer goods and retail.

Portfolio Pulse from Benzinga Newsdesk

February 15, 2024 | 2:01 pm

SHTLF

South32 Ltd (OTC:SHTLF), an Australian mining company, announced a $2.16 billion investment in the Hermosa project in Arizona, aiming to produce critical minerals zinc and manganese. This investment aligns with the Biden administration's clean energy vision and is expected to make Hermosa one of the world's largest zinc mines. Despite a recent 92% decrease in profits, South32 is optimistic about the global demand for zinc outpacing production by 2031.

Portfolio Pulse from Stjepan Kalinic

February 15, 2024 | 1:44 pm

DWAC

Digital World Acquisition Corp (NASDAQ:DWAC) shares surged after the SEC declared its registration statement on Form S-4 effective for its proposed business combination with Trump Media & Technology Group, owner of Truth Social. The move is seen as a step forward for the merger, with a shareholder meeting to vote on the combination expected soon. DWAC's stock has been rising amid increasing likelihood of Donald Trump's return to the White House, with a recent poll showing him leading the Republican primary race.

Portfolio Pulse from Adam Eckert

February 15, 2024 | 1:43 pm

FRLA

OCLN

OriginClear, Inc. (OCLN) and Fortune Rise Acquisition Corporation (FRLA) announced the filing of a Form S-4 registration statement for a proposed business combination with OCLN's subsidiary Water On Demand (WODI). The transaction, valued at approximately $72 million, aims to list the combined company under the ticker symbol 'WODI' on Nasdaq in the second half of 2024, subject to approvals. The deal is expected to enhance OriginClear's water-as-a-service network and accelerate growth through acquisitions.

Portfolio Pulse from Benzinga Newsdesk

February 15, 2024 | 1:41 pm

JAGX

Jaguar Health announced an agreement with the FDA on a clinical trial protocol for full approval of Canalevia-CA1, a treatment for chemotherapy-induced diarrhea in dogs. Canalevia-CA1, a canine-specific formulation of crofelemer from the Croton lechleri tree, is currently the only FDA conditionally approved treatment for this condition.

Portfolio Pulse from Benzinga Newsdesk

February 15, 2024 | 1:37 pm